If the boceprevir svr rate ends up 20 points higher than the control arm, then i think it suggests that the sgp peg is less effective than the roche peg, and that would not be good for boceprevir, since sgp will never use the roche peg in a boceprevir trial. Its hard to see boceprevir ending up the winner.
Market Data 
Markets 
AI
